THE global leader in  blood management solutions for our customers

RSS Content

Haemonetics Sets Date for Investor / Analyst Meeting - June 19, 2017

BRAINTREE, Mass., May 22, 2017 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that it will host an investor and analyst meeting on Monday, June 19th from 10:00am to 2:00pm Eastern Time at The Sheraton Boston Hotel, 39 Dalton Street in Boston, Massachusetts.

HAE logo April 2016.

Attendees will be offered demonstrations of the Company's wide array of products and the opportunity to meet management. The meeting agenda will include reviews of fiscal 2017 results and fiscal 2018 guidance, updates on the Company's strategic plans and growth opportunities, and the underlying assumptions for the Company's long-range goals, followed by a question and answer period.

Participants will include Haemonetics' CEO, Christopher Simon, and CFO, William Burke, as well as leaders of the Plasma, Hospital and Blood Center business units.                              

The meeting is open to analysts, shareholders, and others in the investment community by invitation. Invitations will follow along with instructions for on-line registration. Other audiences are welcome to participate in the presentation and the question / answer portions of the meeting via live webcast. Webcast link: http://edge.media-server.com/m/p/42mzp3ed.   

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative hematology products and solutions, to help customers improve patient care and reduce the cost of healthcare. The Company's technologies address important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.      

CONTACT:
Gerry Gould, VP- Investor Relations
(781) 356-9402
gerry.gould@haemonetics.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/haemonetics-sets-date-for-investor--analyst-meeting--june-19-2017-300461560.html

SOURCE Haemonetics Corporation